UPMC Hillman Cancer Center and University of Pittsburgh physicians and researchers will be well-represented at the 2019 American Society of Clinical Oncology (ASCO) annual meeting in Chicago May 31 – June 4. Faculty research will be featured in both oral presentations and poster sessions.
Saturday, June 1
Educational Session – 8 to 9:15 a.m.
The Management and Prevention of Anal Squamous Cell Carcinoma
Surveillance and the Management of Anal Intraepithelial Neoplasia in the HIV and Non-HIV Patient
Ian McGowan, MD, PhD, FRCP
Poster Sessions – 8 to 11 a.m.
Poster Board: #444, Abstract 10062
Morbidity and mortality in a national cohort of pediatric patients with hemophagocytic lymphohistiocytosis.
Stephen William Allen, MD
Interactive Case-Based Sessions – 4:45 – 5:45 p.m.
Many Challenges, Many Opportunities: Cancer Prevention in Patients With Multiple Risk Factors
Assessment and Management of Germline Mutations Predisposing to Breast Cancer
Phuong L. Mai, MD, MS
Poster Discussion Session – 3 to 4:30 p.m.
Poster Board: #338 • Abstract 11015
Clinical activity of pembrolizumab (P) in undifferentiated pleomorphic sarcoma (UPS) and dedifferentiated/pleomorphic liposarcoma (LPS): Final results of SARC028 expansion cohorts.
Melissa Amber Burgess, MD
Poster Discussion Session – 4:30 to 6 p.m.
Health Services Research, Clinical Informatics, and Quality of Care
Poster Board: #210 • Abstract 6519
Quantification of the financial burden of antineoplastic agent price increases.
Michail Alevizakos, MD
Sunday, June 2
Education Session – 9:45 to 11 a.m.
Wanna Get Away? Continuous Treatments Versus Treatment Holidays in Gynecologic Cancer
Changing the Perspective for “Successful” Maintenance Therapy
Ronald J. Buckanovich, MD
Approaches to High-Risk Resected Stage II and III Melanoma
Stage II Melanoma: What Patients Are Appropriate for Adjuvant Therapy?
Jason J. Luke, MD, FACP
Poster Discussion Session – 11:15 a.m. to 12:15 p.m.
Breast Cancer—Metastatic
Poster Board: #94 • Abstract 1013
Phase II COLET study: Atezolizumab (A) + cobimetinib (C) + paclitaxel (P)/nab-paclitaxel (nP) as first-line (1L) treatment (tx) for patients (pts) with locally advanced or metastatic triple-negative breast cancer (mTNBC).
Adam Brufsky, MD, PhD
Monday, June 3
Education Session – 8 to 9:15 a.m.
Management of Uncommon and Rare Breast Cancers
Natural History and Pathology of Rare Breast Cancer Subtypes
Peter C. Lucas, MD, PhD
Poster Session – 8 to 11 a.m.
Gastrointestinal (Colorectal) Cancer
Poster Board: #68 • Abstract 3576
High incidence of advanced stage cancer and prolonged rectal bleeding history before diagnosis in young-onset patients with colorectal cancer.
Gurprataap Singh Sandhu, MBBS
Oral Abstract Session – 8 to 11 a.m.
Genitourinary (Nonprostate) Cancer
Abstract 4502: Randomized, double-blind phase III study of pazopanib versus placebo in patients with metastatic renal cell carcinoma who have no evidence of disease following metastasectomy: A trial of the ECOG-ACRIN cancer research group (E2810).
Leonard Joseph Appleman, MD, PhD
Poster Session – 1:15 – 4:15 p.m.
Melanoma/Skin Cancers
Poster Board: #142 • Abstract 9571
Association of baseline neutrophil-to-lymphocyte ratio (NLR) with response and survival in advanced melanoma (MEL) receiving PD-1 inhibitors.
Amit Hemadri, MD
Poster Board: #143 • Abstract 9572
Association of medication (Med) and antibiotic (Abx) use with response and survival in advanced melanoma (MEL) receiving PD-1 inhibitors.
Amit Hemadri, MD
Poster Board: #150 • Abstract 9579
Association of baseline body mass index (BMI) with response and survival in patients (Pts) with advanced melanoma (MEL) receiving PD-1 inhibitors.
Amit Hemadri, MD
Poster Board: #157 • Abstract 9586
A phase I study of neoadjuvant combination immunotherapy in locally/regionally advanced melanoma.
Yana Najjar, MD
Cancer Prevention, Hereditary Genetics, and Epidemiology
Poster Board: #64 • Abstract 1570
Sex-specific mortality trends in adolescents and young adults with cancer from 2007 to 2016.
Allison Close, MD
Poster Discussion Session – 4:30 to 6 p.m.
Melanoma/Skin Cancers
Peripheral Blood and Tumor Microenvironment Considerations for Immunotherapy
Jason J. Luke, MD, FACP
Discussing Abstract(s): 9515, 9516, 9517
Symptoms and Survivorship
Poster Board: #291 • Abstract 11599
Interim analyses of the efficacy of a collaborative care intervention for patients diagnosed with comorbid cancer and depression.
Jennifer Lynne Steel, PhD
